Abstract | PURPOSE: EXPERIMENTAL DESIGN: Cytotoxic effects were evaluated in human small cell lung cancer cell lines [H69, H82, and vascular endothelial growth factor ( VEGF)-secreting cells (SBC-3/ VEGF and its mock transfectant SBC-3/Neo)]. In vivo antitumor effects were evaluated in SBC-3/Neo-bearing and SBC-3/ VEGF-bearing mice after NK012/CDDP or CPT-11/CDDP administration on days 0, 7, and 14. Drug distribution was analyzed by high-performance liquid chromatography or fluorescence microscopy, and the small intestine was pathologically examined. RESULTS: The in vitro growth-inhibitory effects of NK012 were 198- to 532-fold more potent than those of CPT-11. A significant difference in the relative tumor volume on day 30 was found between NK012/CDDP and CPT-11/CDDP treatments (P = 0.0058). Inflammatory changes in the small intestinal mucosa were rare in all NK012-treated mice but were commonly observed in CPT-11-treated mice. Moreover, a large amount of CPT-11 was excreted into the feces and high CPT-11 concentration was detected in the small intestinal epithelium. On the other hand, a small amount of NK012 was found in the feces and NK012 was weakly and uniformly distributed in the mucosal interstitium. CONCLUSIONS: NK012/CDDP combination may be a promising candidate regimen against lung cancer without severe diarrhea toxicity and therefore warrants further clinical evaluation.
|
Authors | Tatsuya Nagano, Masahiro Yasunaga, Koichi Goto, Hirotsugu Kenmotsu, Yoshikatsu Koga, Jun-Ichiro Kuroda, Yoshihiro Nishimura, Takashi Sugino, Yutaka Nishiwaki, Yasuhiro Matsumura |
Journal | Clinical cancer research : an official journal of the American Association for Cancer Research
(Clin Cancer Res)
Vol. 15
Issue 13
Pg. 4348-55
(Jul 01 2009)
ISSN: 1557-3265 [Electronic] United States |
PMID | 19509138
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- VEGFA protein, human
- Vascular Endothelial Growth Factor A
- Irinotecan
- Cisplatin
- Camptothecin
|
Topics |
- Animals
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, pharmacology, therapeutic use)
- Camptothecin
(administration & dosage, adverse effects, analogs & derivatives, pharmacology)
- Cisplatin
(administration & dosage, adverse effects, pharmacology)
- Female
- Humans
- Intestinal Mucosa
(drug effects, pathology)
- Irinotecan
- Lung Neoplasms
(drug therapy, genetics, metabolism, pathology)
- Mice
- Mice, Inbred BALB C
- Mice, Nude
- Small Cell Lung Carcinoma
(drug therapy, genetics, metabolism, pathology)
- Tumor Cells, Cultured
- Vascular Endothelial Growth Factor A
(genetics, metabolism)
- Xenograft Model Antitumor Assays
|